Pharmaceuticals

Biosimilar Hormones Market Forecast 2026–2035: How to Leverage Market Growth

February 12, 2026February 12, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the biosimilar hormones market from 2026–2035 with trusted insights from The Business Research Company

How much larger will the Biosimilar Hormones Market be in 2030 compared with 2026?

Significant expansion has been observed in the biosimilar hormones market size recently. This market is projected to expand from $6.22 billion in 2025 to $7.68 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 23.5%. Historically, this growth has been driven by factors such as the increasing incidence of diabetes and various hormonal conditions, the elevated expense of conventional branded hormone treatments, a burgeoning elderly demographic, heightened understanding of hormone replacement therapies, and the expanding reach of hospital and retail pharmacy services.

The biosimilar hormones market is poised for substantial expansion in the upcoming years, with projections indicating it will reach $18.12 billion by 2030, growing at a compound annual growth rate (CAGR) of 23.9%. This anticipated growth throughout the forecast period stems from the expiration of patents for significant biologic hormones, increasing regulatory encouragement for biosimilars, a rising need for economical endocrine therapies, the broadening of online pharmacy distribution avenues, and heightened investment in biosimilar research and development. Dominant trends during this period are expected to include the escalating adoption of biosimilar hormones as more affordable alternatives, an amplified demand for insulin and growth hormone biosimilars, greater acceptance of biosimilar hormone treatments among medical practitioners, the wider application of biosimilars in chronic and lifestyle-related illnesses, and enhanced regulatory frameworks that facilitate biosimilar approvals.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3432&type=smp

What Drivers Are Guiding Growth Patterns In The Biosimilar Hormones Market?

The expansion of the biosimilar hormones market is anticipated to be driven by increasing healthcare expenditure. This spending represents the aggregate financial outlay by individuals, organizations, and governments for the prevention, treatment, and management of various health conditions. The escalation in healthcare costs is primarily attributed to breakthroughs in medical technology, as advanced diagnostic tools, treatments, and novel therapies frequently entail higher expenses, contributing to a greater overall financial commitment in the healthcare sector. Such elevated spending fosters the adoption of biosimilar hormones by creating a greater need for economical treatments and enhancing patient accessibility across diverse healthcare systems. For example, data from December 2024, provided by the Centers for Medicare & Medicaid Services, a US-based agency responsible for administering the Medicare and Medicaid programs, indicated that in 2023, U.S. health care expenditures rose by 7.5%, reaching $4.9 trillion, or approximately $14,570 per person. Consequently, the upward trend in healthcare expenditure is stimulating the growth of the biosimilar hormones market.

How Is The Biosimilar Hormones Market Divided Into Segments?

The biosimilar hormones market covered in this report is segmented –

1) By Type: Teriparatide Biosimilars, Follitropin Alfa Biosimilars, Insulin Biosimilars, Somatropin Biosimilars, Other Types

2) By Application: Research & Biotechnology, Therapeutics, Other Applications

3) By Distribution Channel: Hospital And Retail Pharmacy, Online Pharmacy/pharmacy, Specialty Clinics

Subsegments:

1) By Teriparatide Biosimilars: Osteoporosis Treatment, Bone Health Maintenance

2) By Follitropin Alfa Biosimilars: Infertility Treatment, Assisted Reproductive Technology (ART)

3) By Insulin Biosimilars: Type 1 Diabetes Management, Type 2 Diabetes Management

4) By Somatropin Biosimilars: Growth Hormone Deficiency Treatment, Pediatric Growth Disorders

5) By Other Types: Thyroid Hormones, Corticosteroids

Which Trends Are Guiding The Evolution Of The Biosimilar Hormones Market?

Major companies in the biosimilar hormones market are introducing innovative products, such as the Sogroya (somapacitan-beco) injection, to enhance their market profitability. Sogroya (somapacitan-beco) is a prescribed human growth hormone (GH) analog used to treat individuals diagnosed with growth hormone deficiency (GHD). For instance, in April 2023, Novo Nordisk, a pharmaceutical company based in Denmark, received FDA approval for a new indication for Sogroya (somapacitan-beco) injection. This approval is for the treatment of children aged 2.5 years and older who suffer from growth failure due to insufficient endogenous growth hormone secretion. Sogroya is notable as the sole once-weekly growth hormone (GH) therapy available for both children and adults. The approval was supported by findings from the phase 3 REAL4 trial, which demonstrated Sogroya’s effectiveness in addressing growth hormone deficiency (GHD) in pediatric patients.

Which Major Firms Are Strengthening Their Position In The Biosimilar Hormones Market?

Major companies operating in the biosimilar hormones market are Teva Pharmaceutical Industries Ltd., Gedeon Richter Plc., Intas Pharmaceuticals Ltd., Biocon Limited, Mylan, Sanofi, Sandoz Group AG, LG Life Sciences, Ferring Pharmaceuticals, GC Pharma, Pfizer Inc., Dr. Reddy’s Laboratories, Amgen Inc., Eli Lilly and Company, Celltrion Inc., Samsungbioepis Co.Ltd, Merck & Co., Biogen Inc., Boehringer Ingelheim, Alvotech, Cipla Limited, Lupin Ltd., Stada Arzneimittel AG, Torrent Pharmaceuticals, Zydus Cadila, Accord Healthcare, Hetero Drugs, Wockhardt

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/biosimilar-hormone-global-market-report

Which Region Shows The Strongest Potential For Future Expansion In The Biosimilar Hormones Market?

North America was the largest region in the biosimilar hormones market in 2025. The regions covered in the biosimilar hormones market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Biosimilar Hormones Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=3432&type=smp

Browse Through More Reports Similar to the Global Biosimilar Hormones Market 2026, By The Business Research Company

Hormonal Contraceptives Market Report 2026

https://www.thebusinessresearchcompany.com/report/hormonal-contraceptives-global-market-report

Biosimilar Growth Hormone Market Report 2026

https://www.thebusinessresearchcompany.com/report/biosimilar-growth-hormone-global-market-report

Parathyroid Hormones Market Report 2026

https://www.thebusinessresearchcompany.com/report/parathyroid-hormones-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795